Pain and Addiction

  • Lynda T. Wells


Chronic pain and addiction are complex, neurobiologic diseases with distinct and overlapping pathologies. Their diagnosis, and treatment as co-existing diseases, is challenging and requires multimodal, multidisciplinary disease management. The physiology of these diseases and the positive and negative effects of opioid analgesics in their treatment are discussed. The impact of psychiatric comorbidities on outcomes is characterized. Clinical treatment paradigms are suggested.


Pain Addiction Nociception Opioids Screening Tools “Universal Precautions” Glia Multidisciplinary treatment 


  1. 1.
    Ahmad S, Dahllund L, Eriksson AB, Hellgren D, Karlsson U, Lund PE, Meijer IA, Meury L, Mills T, Moody A, Morinville A, Morten J, O’Donnell D, Raynoschek C, Salter H, Rouleau GA, Krupp JJ (2007) A stop codon mutation in SCN9A causes lack of pain sensation. Hum Mol Genet 16:2114–2121PubMedCrossRefGoogle Scholar
  2. 2.
    Allen NJ, Barres BA (2009) Neuroscience: Glia – more than just brain glue. Nature 457:675–677PubMedCrossRefGoogle Scholar
  3. 3.
    American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  4. 4.
    Bantick SJ, Wise RG, Ploghaus A, Clare S, Smith SM, Tracey I (2002) Imaging how attention modulates pain in humans using functional MRI. Brain 125:310–319PubMedCrossRefGoogle Scholar
  5. 5.
    Belgrade MJ, Schamber CD, Lindgren BR (2006) The DIRE score: predicting outcomes of opioid prescribing for chronic pain [see comment]. J Pain 7:671–681PubMedCrossRefGoogle Scholar
  6. 6.
    Butler SF, Budman SH, Fernandez K, Jamison RN (2004) Validation of a screener and opioid assessment measure for patients with chronic pain. Pain 112:65–75PubMedCrossRefGoogle Scholar
  7. 7.
    Butler SF, Budman SH, Fernandez KC, Houle B, Benoit C, Katz N, Jamison RN (2007) Development and validation of the Current Opioid Misuse Measure. Pain 130:144–156PubMedCrossRefGoogle Scholar
  8. 8.
    Chelminski PR, Ives TJ, Felix KM, Prakken SD, Miller TM, Perhac JS, Malone RM, Bryant ME, DeWalt DA, Pignone MP (2005) A primary care, multi-disciplinary disease management program for opioid-treated patients with chronic non-cancer pain and a high burden of psychiatric comorbidity. BMC Health Services Res 5:3CrossRefGoogle Scholar
  9. 9.
    Chou R, Qaseem A, Snow V, Casey D, Cross JT Jr, Shekelle P, Owens DK, Clinical Efficacy Assessment Subcommittee of the American College of Physicians, American College of Physicians, American Pain Society Low Back Pain Guidelines Panel (2007) Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American college of physicians and the American pain society [see comment] [erratum appears in Ann Intern Med 2008 Feb 5;148(3):247–248] [summary for patients in Ann Intern Med 2007 Oct 2;147(7):I45]. Ann Intern Med 147:478–491PubMedGoogle Scholar
  10. 10.
    Chou R, Fanciullo GJ, Fine PG, Adler JA, Ballantyne JC, Davies P, Donovan MI, Fishbain DA, Foley KM, Fudin J, Gilson AM, Kelter A, Mauskop A, O’Connor PG, Passik SD, Pasternak GW, Portenoy RK, Rich BA, Roberts RG, Todd KH, Miaskowski C, American Pain Society-American Academy of Pain Medicine Opioids Guidelines P (2009) Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain [see comment]. J Pain 10:113–130PubMedCrossRefGoogle Scholar
  11. 11.
    Chou R, Loeser JD, Owens DK, Rosenquist RW, Atlas SJ, Baisden J, Carragee EJ, Grabois M, Murphy DR, Resnick DK, Stanos SP, Shaffer WO, Wall EM (2009) American pain society low back pain guideline panel. Interventional therapies, surgery, and interdisciplinary rehabilitation for low back pain: an evidence-based clinical practice guideline for the American pain society. Spine 34:1066–1077PubMedCrossRefGoogle Scholar
  12. 12.
    Clohisy DR, Mantyh PW (2003) Bone cancer pain. Cancer 97:866–873PubMedCrossRefGoogle Scholar
  13. 13.
    Compton P, Darakjian J, Miotto K (1998) Screening for addiction in patients with chronic pain and “problematic” substance use: evaluation of a pilot assessment tool. J Pain Symptom Manage 16:355–363PubMedCrossRefGoogle Scholar
  14. 14.
    Cox JJ, Reimann F, Nicholas AK, Thornton G, Roberts E, Springell K, Karbani G, Jafri H, Mannan J, Raashid Y, Al-Gazali L, Hamamy H, Valente EM, Gorman S, Williams R, McHale DP, Wood JN, Gribble FM, Woods CG (2006) An SCN9A channelopathy causes congenital inability to experience pain [see comment]. Nature 444:894–898PubMedCrossRefGoogle Scholar
  15. 15.
    Craig AD (2003) A new view of pain as a homeostatic emotion. Trends Neurosci 26:303–307PubMedCrossRefGoogle Scholar
  16. 16.
    D’Arcy Y, McCarberg B (2007) Pain management: patients with a substance use disorder. Nurse Pract 32:36–44PubMedCrossRefGoogle Scholar
  17. 17.
    Dackis CA, O’Brien CP (2001) Cocaine dependence: a disease of the brain’s reward centers. J Subst Abuse Treat 21:111–117PubMedCrossRefGoogle Scholar
  18. 18.
    Dowling K, Storr CL, Chilcoat HD (2006) Potential influences on initiation and persistence of extramedical prescription pain reliever use in the US population. Clin J Pain 22:776–783PubMedCrossRefGoogle Scholar
  19. 19.
    Edlund MJ, Sullivan M, Steffick D, Harris KM, Wells KB (2007) Do users of regularly prescribed opioids have higher rates of substance use problems than nonusers? Pain Med 8:647–656PubMedCrossRefGoogle Scholar
  20. 20.
    Fields H (2004) State-dependent opioid control of pain. Nat Rev Neurosci 5:565–575PubMedCrossRefGoogle Scholar
  21. 21.
    Fields HL (2007) Should we be reluctant to prescribe opioids for chronic non-malignant pain? [comment]. Pain 129:233–234PubMedCrossRefGoogle Scholar
  22. 22.
    Fields HL (2007) Understanding how opioids contribute to reward and analgesia [see comment]. Reg Anesth Pain Med 32:242–246PubMedGoogle Scholar
  23. 23.
    Fishman SM, Wilsey B, Yang J, Reisfield GM, Bandman TB, Borsook D (2000) Adherence monitoring and drug surveillance in chronic opioid therapy. J Pain Symptom Manage 20:293–307PubMedCrossRefGoogle Scholar
  24. 24.
    Fishman SM, Papazian JS, Gonzalez S, Riches PS, Gilson A (2004) Regulating opioid prescribing through prescription monitoring programs: balancing drug diversion and treatment of pain. Pain Med 5:309–324PubMedCrossRefGoogle Scholar
  25. 25.
    Fleming MF, Balousek SL, Klessig CL, Mundt MP, Brown DD (2007) Substance use disorders in a primary care sample receiving daily opioid therapy. J Pain 8:573–582PubMedGoogle Scholar
  26. 26.
    Gourlay DL, Heit HA, Almahrezi A (2005) Universal precautions in pain medicine: a rational approach to the treatment of chronic pain [see comment]. Pain Med 6:107–112PubMedCrossRefGoogle Scholar
  27. 27.
    Heit HA (2001) The truth about pain management: the difference between a pain patient and an addicted patient. Eur J Pain 5(Suppl A): 27–29PubMedCrossRefGoogle Scholar
  28. 28.
    Hnasko TS, Sotak BN, Palmiter RD (2005) Morphine reward in dopamine-deficient mice. Nature 438:854–857PubMedCrossRefGoogle Scholar
  29. 29.
    Hoffman HG, Richards TL, Coda B, Bills AR, Blough D, Richards AL, Sharar SR (2004) Modulation of thermal pain-related brain activity with virtual reality: evidence from fMRI. Neuroreport 15:1245–1248PubMedCrossRefGoogle Scholar
  30. 30.
    Hojsted J, Sjogren P (2007) Addiction to opioids in chronic pain patients: a literature review. Eur J Pain 11:490–518PubMedCrossRefGoogle Scholar
  31. 31.
    Jamison RN, Kauffman J, Katz NP (2000) Characteristics of methadone maintenance patients with chronic pain. J Pain Symptom Manage 19:53–62PubMedCrossRefGoogle Scholar
  32. 32.
    Jovey RD (2008) Pain and addiction: prevalence, neurobiology, and definitions. In: Castro-Lopes J, Raja S, Schmelz M (eds) Pain 2008—an updated review. IASP, SeattleGoogle Scholar
  33. 33.
    Jung B, Reidenberg MM (2007) Physicians being deceived [see comment]. Pain Med 8:433–437PubMedCrossRefGoogle Scholar
  34. 34.
    Kahan M, Srivastava A, Wilson L, Gourlay D, Midmer D (2006) Misuse of and dependence on opioids: study of chronic pain patients. Can Fam Physician 52:1081–1087PubMedGoogle Scholar
  35. 35.
    Katz N (2007) Opioids: after thousands of years, still getting to know you. Clin J Pain 23:303–306PubMedCrossRefGoogle Scholar
  36. 36.
    Katz NP, Adams EH, Benneyan JC, Birnbaum HG, Budman SH, Buzzeo RW, Carr DB, Cicero TJ, Gourlay D, Inciardi JA, Joranson DE, Kesslick J, Lande SD (2007) Foundations of opioid risk management. Clin J Pain 23:103–118PubMedCrossRefGoogle Scholar
  37. 37.
    Kirsh KL, Jass C, Bennett DS, Hagen JE, Passik SD (2007) Initial development of a survey tool to detect issues of chemical coping in chronic pain patients. Palliat Support Care 5:219–226PubMedCrossRefGoogle Scholar
  38. 38.
    Kuehn BM (2005) Role of environment in addiction probed. JAMA 294:2953–2955PubMedCrossRefGoogle Scholar
  39. 39.
    Kuehn BM (2007) Opioid prescriptions soar: increase in legitimate use as well as abuse. JAMA 297:249–251PubMedCrossRefGoogle Scholar
  40. 40.
    Kuehn BM (2007) Scientists probe ways to curb opioid abuse without hindering pain treatment. JAMA 297:1965–1967PubMedCrossRefGoogle Scholar
  41. 41.
    Littlejohn C, Baldacchino A, Bannister J (2004) Chronic non-cancer pain and opioid dependence. J R Soc Med 97:62–65PubMedCrossRefGoogle Scholar
  42. 42.
    Manchikanti L, Manchukonda R, Damron KS, Brandon D, McManus CD, Cash K (2006) Does adherence monitoring reduce controlled substance abuse in chronic pain patients? Pain Phys 9:57–60Google Scholar
  43. 43.
    Mao J (2008) Opioid-Induced Hyperalgesia. Pain Clin Updates 16Google Scholar
  44. 44.
    Margolis EB, Lock H, Chefer VI, Shippenberg TS, Hjelmstad GO, Fields HL (2006) Kappa opioids selectively control dopaminergic neurons projecting to the prefrontal cortex. Proc Natl Acad Sci USA 103:2938–2942PubMedCrossRefGoogle Scholar
  45. 45.
    Martell BA, O’Connor PG, Kerns RD, Becker WC, Morales KH, Kosten TR, Fiellin DA (2007) Systematic review: opioid treatment for chronic back pain: prevalence, efficacy, and association with addiction [see comment]. Ann Intern Med 146:116–127PubMedGoogle Scholar
  46. 46.
    McLellan AT, Kushner H, Metzger D, Peters R, Smith I, Grissom G, Pettinati H, Argeriou M (1992) The Fifth Edition of the Addiction Severity Index. J Subst Abuse Treat 9:199–213PubMedCrossRefGoogle Scholar
  47. 47.
    Mehta V, Langford RM (2006) Acute pain management for opioid dependent patients [see comment]. Anaesthesia 61:269–276PubMedCrossRefGoogle Scholar
  48. 48.
    Meng ID, Johansen JP, Harasawa I, Fields HL (2005) Kappa opioids inhibit physiologically identified medullary pain modulating neurons and reduce morphine antinociception. J Neurophysiol 93:1138–1144PubMedCrossRefGoogle Scholar
  49. 49.
    Miller NS, Swiney T, Barkin RL (2006) Effects of opioid prescription medication dependence and detoxification on pain perceptions and self-reports. Am J Therapeut 13:436–444CrossRefGoogle Scholar
  50. 50.
    Nader MA, Czoty PW, Gould RW, Riddick NV (2008) Review. Positron emission tomography imaging studies of dopamine receptors in primate models of addiction. Phil Trans R Soc B 363:3223–3232PubMedCrossRefGoogle Scholar
  51. 51.
    Naliboff BD, Wu SM, Pham Q (2006) Clinical considerations in the treatment of chronic pain with opioids. J Clin Psychol 62:1397–1408PubMedCrossRefGoogle Scholar
  52. 52.
    Narita M, Kaneko C, Miyoshi K, Nagumo Y, Kuzumaki N, Nakajima M, Nanjo K, Matsuzawa K, Yamazaki M, Suzuki T (2006) Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala. Neuropsychopharmacology 31:739–750PubMedCrossRefGoogle Scholar
  53. 53.
    Office of Statistical Analysis (2006) How young adults obtain prescription pain relievers for non-medical use. Administration SAaMHSGoogle Scholar
  54. 54.
    Passik SD, Kirsh KL (2004) Assessing aberrant drug-taking behaviors in the patient with chronic pain. Curr Pain Headache Rep 8:289–294PubMedCrossRefGoogle Scholar
  55. 55.
    Passik SD, Kirsh KL, Whitcomb L, Portenoy RK, Katz NP, Kleinman L, Dodd SL, Schein JR (2004) A new tool to assess and document pain outcomes in chronic pain patients receiving opioid therapy. Clin Ther 26:552–561PubMedCrossRefGoogle Scholar
  56. 56.
    Passik SD, Kirsh KL, Casper D (2008) Addiction-related assessment tools and pain management: instruments for screening, treatment planning, and monitoring compliance. Pain Med 9: S145–S166CrossRefGoogle Scholar
  57. 57.
    Pawl R (2007) Opioids. Surg Neurol 68:646–647PubMedCrossRefGoogle Scholar
  58. 58.
    Perl ER (2007) Ideas about pain, a historical view. Nat Rev Neurosci 8:71–80PubMedCrossRefGoogle Scholar
  59. 59.
    Popenhagen MP (2006) Collaborative practice. Undertreatment of pain and fears of addiction in pediatric chronic pain patients: how do we stop the problem? J Spec Pediatr Nurs 11:61–67PubMedCrossRefGoogle Scholar
  60. 60.
    Rao SG, Gendreau JF, Kranzler JD (2007) Understanding the fibromyalgia syndrome. Psychopharmacol Bull 40:24–67PubMedGoogle Scholar
  61. 61.
    Rich BA (2007) Ethics of opioid analgesia for chronic noncancer pain. Pain Clin UpdatesGoogle Scholar
  62. 62.
    Saffier K, Colombo C, Brown D, Mundt MP, Fleming MF (2007) Addiction Severity Index in a chronic pain sample receiving opioid therapy. J Subst Abuse Treat 33:303–311PubMedCrossRefGoogle Scholar
  63. 63.
    Savage SR, Joranson DE, Covington EC, Schnoll SH, Heit HA, Gilson AM (2003) Definitions related to the medical use of opioids: evolution towards universal agreement [see comment]. J Pain Symptom Manage 26:655–667PubMedCrossRefGoogle Scholar
  64. 64.
    Schieffer BM, Pham Q, Labus J, Baria A, Van Vort W, Davis P, Davis F, Naliboff BD (2005) Pain medication beliefs and medication misuse in chronic pain. J Pain 6:620–629PubMedCrossRefGoogle Scholar
  65. 65.
    Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK (2008) Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses [see comment]. Arch Gen Psychiatry 65:220–231PubMedCrossRefGoogle Scholar
  66. 66.
    Streltzer J, Johansen L (2006) Prescription drug dependence and evolving beliefs about chronic pain management [see comment]. Am J Psychiatry 163:594–598PubMedCrossRefGoogle Scholar
  67. 67.
    Sullivan MD, Edlund MJ, Steffick D, Unutzer J (2005) Regular use of prescribed opioids: association with common psychiatric disorders. Pain 119:95–103PubMedCrossRefGoogle Scholar
  68. 68.
    Sullivan MD, Edlund MJ, Zhang L, Unutzer J, Wells KB (2006) Association between mental health disorders, problem drug use, and regular prescription opioid use [see comment]. Archiv Intern Med 166:2087–2093CrossRefGoogle Scholar
  69. 69.
    Suzuki T, Kishimoto Y, Ozaki S, Narita M (2001) Mechanism of opioid dependence and interaction between opioid receptors. Eur J Pain 5(Suppl A):63–65PubMedCrossRefGoogle Scholar
  70. 70.
    Trafton JA, Oliva EM, Horst DA, Minkel JD, Humphreys K (2004) Treatment needs associated with pain in substance use disorder patients: implications for concurrent treatment. Drug Alcohol Depend 73:23–31PubMedCrossRefGoogle Scholar
  71. 71.
    Treede RD (2006) Assessment of pain as an emotion in animals and in humans [comment]. Exp Neurol 197:1–3PubMedCrossRefGoogle Scholar
  72. 72.
    US Department of Veterans Affairs (2005) VA office of quality performance: opioid therapy for chronic pain clinical practice guidelines. Management VANPGoogle Scholar
  73. 73.
    Vlaeyen JWS, Crombez G (2007) Fear and pain. Pain Clin Updates 15Google Scholar
  74. 74.
    Wang HY, Friedman E, Olmstead MC, Burns LH (2005) Ultra-low-dose naloxone suppresses opioid tolerance, dependence and associated changes in mu opioid receptor-G protein coupling and Gbetagamma signaling. Neuroscience 135:247–261PubMedCrossRefGoogle Scholar
  75. 75.
    Wasan AD, Butler SF, Budman SH, Benoit C, Fernandez K, Jamison RN (2007) Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. Clin J Pain 23:307–315PubMedCrossRefGoogle Scholar
  76. 76.
    Watkins LR, Hutchinson MR, Milligan ED, Maier SF (2007) “Listening” and “talking” to neurons: implications of immune activation for pain control and increasing the efficacy of opioids. Brain Res Rev 56:148–169PubMedCrossRefGoogle Scholar
  77. 77.
    Webster LR, Webster RM (2005) Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med 6:432–442PubMedCrossRefGoogle Scholar
  78. 78.
    Weissman DE, Haddox JD (1989) Opioid pseudoaddiction—an iatrogenic syndrome. Pain 36:363–366PubMedCrossRefGoogle Scholar
  79. 79.
    Wu SM, Compton P, Bolus R, Schieffer B, Pham Q, Baria A, Van Vort W, Davis F, Shekelle P, Naliboff BD (2006) The addiction behaviors checklist: validation of a new clinician-based measure of inappropriate opioid use in chronic pain. J Pain Symptom Manage 32:342–351PubMedCrossRefGoogle Scholar
  80. 80.
    Yudko E, Lozhkina O, Fouts A (2007) A comprehensive review of the psychometric properties of the drug abuse screening test. J Subst Abuse Treat 32:189–198PubMedCrossRefGoogle Scholar
  81. 81.
    Ziegler PP (2005) Addiction and the treatment of pain [see comment]. Subst Use Misuse 40:1945–1954PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  1. 1.Departments of Anesthesiology and PediatricsUniversity of VirginiaCharlottesvilleUSA

Personalised recommendations